However, irrespective of the mutational status, AML cells show increased activation of the Cyclin D-CDK4/CDK6 complex [14], suggesting that the deregulation of the CDK/RB axis is a hallmark of AML. The gene discussed is RB1; the disease is acute myeloid leukemia.